Diagnostic and risk stratification aspects of liver fibrosis progression in chronic hepatitis B and C viral infection

Abstract

The treatment strategy and prognosis for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection largely depend on the presence and stage of liver fibrosis. This study aimed to reveal the diagnostic and risk stratification aspects of liver fibrosis progression in patients with chronic HBV and HCV infection. The PubMed database, the Google Scholar search engine, the Cochrane systematic reviews, and the scientific electronic library eLibrary.Ru, as well as the reference lists, were used to search for scientific articles. Relevant aims of the publication review were selected over the period from 2005 to 2021 using the keywords “chronic HBV infection,” “chronic HCV infection,” “liver fibrosis,” “diagnostics,” and “prognosis.” Inclusion criteria were limited to liver fibrosis diagnostics in chronic HBV and HCV infection. Considering biopsy as a gold standard for studying morphological abnormalities in the liver, its indications for serum biomarkers of liver fibrosis and imaging methods assessments are currently significantly limited. Additionally, noninvasive methods are required to monitor the progression of liver fibrosis. The combined use of two unrelated noninvasive methods, for example, transient elastography and one of the serum biomarkers, can improve the accuracy of clinically diagnosing significant liver fibrosis. Considering that the development of liver fibrosis is an unfavorable event in the natural course of chronic HBV and HCV infection, the distribution of patients by risk groups will increase the efficiency of antiviral therapy and improve the disease prognosis.

Keywords

review / chronic HBV infection / chronic HCV infection / liver fibrosis / diagnostics / prognosis

References

[1] Garbuzenko DV. The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection. Vopr. Virusol. 2021; 66(5): 331–339. (in Russ). doi: 10.36233/0507-4088-70.

[2] Гарбузенко Д.В. Роль противовирусной терапии в лечении больных циррозом печени, ассоциированным с хронической HBV- и HCV-инфекцией // Вопросы вирусологии. 2021. Т. 66, № 5. С. 331–339. doi: 10.36233/0507-4088-70.

[3] European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi: 10.1016/j.jhep.2015.04.006

[4] European Association for Study of L., Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis // J Hepatol. 2015. Vol. 63, N 1. P. 237–264. doi: 10.1016/j.jhep.2015.04.006

[5] Yushchuk ND, Klimova EA, Znoiko OO, et al. Protokol diagnostiki i lecheniya bol''nykh virusnymi gepatitami v i s. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2010;20(6):4–60. (In Russ).

[6] Ющук Н.Д., Климова Е.А., Знойко О.О., и др. Протокол диагностики и лечения больных вирусными гепатитами В и С // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010. Т. 20, № 6. С. 4–60.

[7] Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25(2):93–159. doi: 10.3350/cmh.2019.1002

[8] Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B // Clin Mol Hepatol. 2019. Vol. 25, N 2. P. 93–159. doi: 10.3350/cmh.2019.1002

[9] Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger). J Hepatol. 2020;72(3):539–557. doi: 10.1016/j.jhep.2019.11.003

[10] Cornberg M., Lok A.S., Terrault N.A., et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger) // J Hepatol. 2020. Vol. 72, N 3. P. 539–557. doi: 10.1016/j.jhep.2019.11.003

[11] European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–1218. doi: 10.1016/j.jhep.2020.08.018

[12] European Association for the Study of the Liver. Electronic address e.e.e., Clinical Practice Guidelines Panel C., representative E.G.B., Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series // J Hepatol. 2020. Vol. 73, N 5. P. 1170–1218. doi: 10.1016/j.jhep.2020.08.018

[13] Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686–721. doi: 10.1002/hep.31060

[14] Ghany M.G., Morgan T.R., Panel A.-I.H.C.G. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection // Hepatology. 2020. Vol. 71, N 2. P. 686–721. doi: 10.1002/hep.31060

[15] Zeng DW, Dong J, Liu YR, et al. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22(29):6663–6672. doi: 10.3748/wjg.v22.i29.6663

[16] Zeng D.W., Dong J., Liu Y.R., et al. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection // World J Gastroenterol. 2016. Vol. 22, N 29. P. 6663–6672. doi: 10.3748/wjg.v22.i29.6663

[17] Wang H, Xue L, Yan R, et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20(4):e3–10. doi: 10.1111/jvh.12010

[18] Wang H., Xue L., Yan R., et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT // J Viral Hepat. 2013. Vol. 20, N 4. P. e3–10. doi: 10.1111/jvh.12010

[19] Li Q, Ren X, Lu C, et al. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study. Medicine (Baltimore). 2017;96(12):e6336.

[20] Li Q., Ren X., Lu C., et al. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study // Medicine (Baltimore). 2017. Vol. 96, N 12. P. e6336. doi: 10.1097/MD.0000000000006336

[21] doi: 10.1097/MD.0000000000006336

[22] Ma J., Jiang Y., Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection // Eur J Gastroenterol Hepatol. 2013. Vol. 25, N 4. P. 428–434. doi: 10.1097/MEG.0b013e32835cb5dd

[23] Ma J, Jiang Y, Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2013;25(4):428–434. doi: 10.1097/MEG.0b013e32835cb5dd

[24] Schmoyer C.J., Kumar D., Gupta G., Sterling R.K. Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease // Clin Gastroenterol Hepatol. 2020. Vol. 18, N 10. P. 2332–2339 e2331. doi: 10.1016/j.cgh.2020.02.019

[25] Schmoyer CJ, Kumar D, Gupta G, Sterling RK. Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease. Clin Gastroenterol Hepatol. 2020;18(10):2332–2339 e2331. doi: 10.1016/j.cgh.2020.02.019

[26] Degos F., Perez P., Roche B., et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study) // J Hepatol. 2010. Vol. 53, N 6. P. 1013–1021. doi: 10.1016/j.jhep.2010.05.035

[27] Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53(6):1013–1021. doi: 10.1016/j.jhep.2010.05.035

[28] Leroy V., Sturm N., Faure P., et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C // J Hepatol. 2014. Vol. 61, N 1. P. 28–34. doi: 10.1016/j.jhep.2014.02.029

[29] Leroy V, Sturm N, Faure P, et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61(1):28–34. doi: 10.1016/j.jhep.2014.02.029

[30] Marcellin P., Ziol M., Bedossa P., et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B // Liver Int. 2009. Vol. 29, N 2. P. 242–247. doi: 10.1111/j.1478-3231.2008.01802.x

[31] Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242–247. doi: 10.1111/j.1478-3231.2008.01802.x

[32] Stasi C., Arena U., Vizzutti F., et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? // Dig Liver Dis. 2009. Vol. 41, N 12. P. 863–866. doi: 10.1016/j.dld.2009.04.002

[33] Stasi C, Arena U, Vizzutti F, et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Dis. 2009;41(12):863-866. doi: 10.1016/j.dld.2009.04.002

[34] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C // Gastroenterology. 2012. Vol. 142, N 6. P. 1293–1302 e1294. doi: 10.1053/j.gastro.2012.02.017

[35] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293–1302 e1294. doi: 10.1053/j.gastro.2012.02.017

[36] Ganne-Carrie N., Ziol M., de Ledinghen V., et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases // Hepatology. 2006. Vol. 44, N 6. P. 1511–1517. doi: 10.1002/hep.21420

[37] Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44(6):1511–1517. doi: 10.1002/hep.21420

[38] Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography // J Hepatol. 2008. Vol. 48, N 5. P. 835–847. doi: 10.1016/j.jhep.2008.02.008

[39] Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48(5):835–847. doi: 10.1016/j.jhep.2008.02.008

[40] Huang L.L., Yu X.P., Li J.L., et al. Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection // World J Gastroenterol. 2021. Vol. 27, N 7. P. 641–653. doi: 10.3748/wjg.v27.i7.641

[41] Huang LL, Yu XP, Li JL, et al. Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2021; 27(7):641–653. doi: 10.3748/wjg.v27.i7.641

[42] Li X., Zheng S., Xu H., Gao P. Evaluation of non-invasive methods in hepatitis B virus (HBV)-infected patients with normal liver function // Int J Clin Exp Med. 2018. Vol. 11, N 2. P. 792–798.

[43] Li X, Zheng S, Xu H, Gao P. Evaluation of non-invasive methods in hepatitis B virus (HBV)-infected patients with normal liver function. Int J Clin Exp Med. 2018;11(2):792–798.

[44] Khare S., Arora A., Sharma P., et al. Performance of Non-invasive Blood Parameters for Ruling Out Significant Liver Fibrosis in Patients with Chronic Hepatitis B // J Clin Transl Hepatol. 2020. Vol. 8, N 2. P. 143–149. doi: 10.14218/JCTH.2020.00002

[45] Khare S, Arora A, Sharma P, et al. Performance of Non-invasive Blood Parameters for Ruling Out Significant Liver Fibrosis in Patients with Chronic Hepatitis B. J Clin Transl Hepatol. 2020;8(2):143–149. doi: 10.14218/JCTH.2020.00002

[46] Maimone S., Calvaruso V., Pleguezuelo M., et al. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers // J Viral Hepat. 2009. Vol. 16, N 11. P. 769–774. doi: 10.1111/j.1365-2893.2009.01120.x

[47] Maimone S, Calvaruso V, Pleguezuelo M, et al. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J Viral Hepat. 2009;16(11):769–774. doi: 10.1111/j.1365-2893.2009.01120.x

[48] Sporea I., Sirli R.L., Deleanu A., et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies // Ultraschall Med. 2011. Vol. 32 Suppl 1, N. P. S46–52. doi: 10.1055/s-0029-1245360

[49] Sporea I, Sirli RL, Deleanu A, et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall Med. 2011;32 Suppl 1:S46–52. doi: 10.1055/s-0029-1245360

[50] Ueda N., Kawaoka T., Imamura M., et al. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection // BMC Gastroenterol. 2020. Vol. 20, N 1. P. 314. doi: 10.1186/s12876-020-01459-w

[51] Ueda N, Kawaoka T, Imamura M, et al. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. BMC Gastroenterol. 2020;20(1):314. doi: 10.1186/s12876-020-01459-w

[52] Zhuang Y., Ding H., Zhang Y., et al. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Serum Fibrosis Indexes // Radiology. 2017. Vol. 283, N 3. P. 873–882. doi: 10.1148/radiol.2016160131

[53] Zhuang Y, Ding H, Zhang Y, et al. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Serum Fibrosis Indexes. Radiology. 2017;283(3):873–882. doi: 10.1148/radiol.2016160131

[54] Venkatesh S.K., Wang G., Lim S.G., Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B // Eur Radiol. 2014. Vol. 24, N 1. P. 70–78. doi: 10.1007/s00330-013-2978-8

[55] Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24(1):70–78. doi: 10.1007/s00330-013-2978-8

[56] Xu X.Y., Wang W.S., Zhang Q.M., et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis // World J Clin Cases. 2019. Vol. 7, N 15. P. 2022–2037. doi: 10.12998/wjcc.v7.i15.2022

[57] Xu XY, Wang WS, Zhang QM, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. World J Clin Cases. 2019; 7(15):2022–2037. doi: 10.12998/wjcc.v7.i15.2022

[58] Cales P., Boursier J., Lebigot J., et al. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? // Aliment Pharmacol Ther. 2017. Vol. 45, N 7. P. 991–1003. doi: 10.1111/apt.13954

[59] Cales P, Boursier J, Lebigot J, et al. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? Aliment Pharmacol Ther. 2017;45(7):991–1003. doi: 10.1111/apt.13954

[60] Liu Y., Dong C.F., Yang G., et al. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B // Liver Int. 2015. Vol. 35, N 3. P. 816–825. doi: 10.1111/liv.12564

[61] Liu Y, Dong CF, Yang G, et al. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. Liver Int. 2015;35(3):816–825. doi: 10.1111/liv.12564

[62] Wong G.L., Wong V.W., Choi P.C., et al. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B // Aliment Pharmacol Ther. 2010. Vol. 31, N 10. P. 1095–1103. doi: 10.1111/j.1365-2036.2010.04276.x

[63] Wong GL, Wong VW, Choi PC, et al. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31(10):1095–1103. doi: 10.1111/j.1365-2036.2010.04276.x

[64] Wong G.L., Chan H.L., Choi P.C., et al. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B // Aliment Pharmacol Ther. 2014. Vol. 39, N 2. P. 197–208. doi: 10.1111/apt.12559

[65] Wong GL, Chan HL, Choi PC, et al. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014; 39(2):197–208. doi: 10.1111/apt.12559

[66] Boursier J., de Ledinghen V., Zarski J.P., et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive // Hepatology. 2012. Vol. 55, N 1. P. 58–67. doi: 10.1002/hep.24654

[67] Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58–67. doi: 10.1002/hep.24654

[68] European Association for the Study of the Liver. Electronic address e.e.e., European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection // J Hepatol. 2017. Vol. 67, N 2. P. 370–398. doi: 10.1016/j.jhep.2017.03.021

[69] European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370–398. doi: 10.1016/j.jhep.2017.03.021

[70] Zeng D.W., Zhang J.M., Liu Y.R., et al. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection // Medicine (Baltimore). 2016. Vol. 95, N 8. P. e2503. doi: 10.1097/MD.0000000000002503

[71] Zeng DW, Zhang JM, Liu YR, et al. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore). 2016;95(8):e2503. doi: 10.1097/MD.0000000000002503

[72] Chao D.T., Lim J.K., Ayoub W.S., et al. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis // Aliment Pharmacol Ther. 2014. Vol. 39, N 4. P. 349–358. doi: 10.1111/apt.12590

[73] Chao DT, Lim JK, Ayoub WS, et al. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther. 2014; 39(4):349-358. doi: 10.1111/apt.12590

[74] Castera L., Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? // Liver Int. 2011. Vol. 31 Suppl 1, N. P. 13–17. doi: 10.1111/j.1478-3231.2010.02380.x

[75] Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int. 2011; 31 Suppl 1:13–17. doi: 10.1111/j.1478-3231.2010.02380.x

[76] Loustaud-Ratti V., Debette-Gratien M., Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift // World J Hepatol. 2018. Vol. 10, N 10. P. 639–644. doi: 10.4254/wjh.v10.i10.639

[77] Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. World J Hepatol. 2018;10(10):639–644. doi: 10.4254/wjh.v10.i10.639

[78] Tachi Y., Hirai T., Toyoda H., et al. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus // PLoS One. 2015. Vol. 10, N 7. P. e0133515. doi: 10.1371/journal.pone.0133515

[79] Tachi Y, Hirai T, Toyoda H, et al. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One. 2015;10(7):e0133515. doi: 10.1371/journal.pone.0133515

[80] Suda T., Okawa O., Masaoka R., et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy // World J Hepatol. 2017. Vol. 9, N 1. P. 64–68. doi: 10.4254/wjh.v9.i1.64

[81] Suda T, Okawa O, Masaoka R, et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol. 2017; 9(1):64–68. doi: 10.4254/wjh.v9.i1.64

[82] Vergniol J., Boursier J., Coutzac C., et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C // Hepatology. 2014. Vol. 60, N 1. P. 65–76. doi: 10.1002/hep.27069

[83] Vergniol J, Boursier J, Coutzac C, et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology. 2014;60(1):65–76. doi: 10.1002/hep.27069

[84] Vutien P., Kim N.J., Moon A.M., et al. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes // Aliment Pharmacol Ther. 2020. Vol. 52, N 11–12. P. 1717-1727. doi: 10.1111/apt.16092

[85] Vutien P, Kim NJ, Moon AM, et al. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. Aliment Pharmacol Ther. 2020;52(11-12):1717–1727. doi: 10.1111/apt.16092

[86] Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance // J Hepatol. 2005. Vol. 42, N 2. P. 188–194. doi: 10.1016/j.jhep.2004.10.026

[87] Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42(2):188–194. doi: 10.1016/j.jhep.2004.10.026

[88] Andersen E.S., Weiland O., Leutscher P., et al. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs // Scand J Gastroenterol. 2011. Vol. 46, N 6. P. 760–766. doi: 10.3109/00365521.2011.565068

[89] Andersen ES, Weiland O, Leutscher P, et al. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol. 2011;46(6):760–766. doi: 10.3109/00365521.2011.565068

[90] Trivedi H.D., Lin S.C., D T.Y.L. Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders // Gastroenterol Hepatol (N Y). 2017. Vol. 13, N 10. P. 587–595. PMC5786821

[91] Trivedi HD, Lin SC, D TYL. Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterol Hepatol (N Y). 2017;13(10):587–595. PMC5786821

RIGHTS & PERMISSIONS

Eco-Vector